GL1X · GenesisL1 explorer

Research workbench

Structure of the tetrameric inhibited form of phosphofructokinase-2 from escherichia COLI

Analyse Structure of the tetrameric inhibited form of phosphofructokinase-2 from… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3CQD
Type
protein
Length
612 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
6-phosphofructokinase isozyme 2
EC
2.7.1.11
UniProt
P06999
Ligands
ATP, MG
Pockets
3 · best druggability 0.76

Structure

x-ray diffraction · 2 distinct chains · 39% helix, 23% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A6-phosphofructokinase isozyme 2 (EC 2.7.1.11)protein30438% helix, 23% strandP06999
B6-phosphofructokinase isozyme 2 (EC 2.7.1.11)protein30840% helix, 23% strandP06999

Ligands and binding sites

  • ATP · Adenosine-5'-triphosphate · ligand · 4 copies · chains A, B
  • MG · Magnesium ion · metal · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16890.760.8170MG, ATP
27220.740.8080MG, ATP
3570.380.8015empty

Interfaces

1 interface between chains.

  • A–B · 1498 Ų buried · 23 hydrogen bonds · protein-protein

Compared structures

  • 3CQD · Structure of the tetrameric inhibited form of phosphofructokinase-2 from Escherichia coli · the same entry in another collection · chain A against A, TM-score 1.00
  • P06999 · AlphaFold monomer V2.0 prediction for ATP-dependent 6-phosphofructokinase isozyme 2… · a predicted model of the same protein · chain B against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.